Avalo Therapeutics, Inc.
General ticker "AVTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $312.6M (TTM average)
Avalo Therapeutics, Inc. follows the US Stock Market performance with the rate: 17.7%.
Estimated limits based on current volatility of 3.8%: low 11.41$, high 12.30$
Factors to consider:
- Total employees count: 33 (+43.5%) as of 2025
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Manufacturing scale up, Capital raising, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.98$, 27.93$]
- 2026-12-31 to 2027-12-31 estimated range: [3.48$, 13.69$]
Financial Metrics affecting the AVTX estimates:
- Negative: with PPE of -3.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: 69.38 < Shareholder equity ratio, % of 71.31 <= 81.92
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Negative: Investing cash flow per share per price, % of -32.91 <= -18.95
- Negative: Industry earnings per price (median), % of -15.99 <= 0
Short-term AVTX quotes
Long-term AVTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1.92MM | $0.44MM | $0.06MM |
| Operating Expenses | $29.27MM | $68.95MM | $72.98MM |
| Operating Income | $-27.35MM | $-68.51MM | $-72.92MM |
| Non-Operating Income | $-4.18MM | $33.50MM | $-5.17MM |
| Interest Expense | $3.42MM | $0.00MM | $0.00MM |
| R&D Expense | $13.78MM | $52.08MM | $50.08MM |
| Income(Loss) | $-31.53MM | $-35.02MM | $-78.09MM |
| Taxes | $0.01MM | $0.11MM | $0.17MM |
| Net Income(Loss)* | $-31.54MM | $-35.13MM | $-78.26MM |
| Stockholders Equity | $7.30MM | $133.03MM | $83.05MM |
| Assets | $20.99MM | $150.73MM | $116.46MM |
| Operating Cash Flow | $-30.68MM | $-49.06MM | $-51.46MM |
| Capital expenditure | $0.16MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-0.13MM | $0.36MM | $-81.72MM |
| Financing Cash Flow | $25.04MM | $175.85MM | $14.59MM |
| Earnings Per Share** | $-113.58 | $-4.32 | $-5.84 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.